False-Positive Amphetamine Urine Screens: What Lawyers Should Request

Connectica, LLC Marketing Staff August 26, 2026 Forensic Toxicology

Prepared by Connectica, LLC marketing staff. This material has not been verified by a trained forensic toxicologist. Read the full Content Disclaimer.

A presumptive amphetamine result can affect a criminal case, employment dispute, professional-license matter, probation proceeding, or other contested decision. But the word positive does not answer every scientific or legal question. The records must show what specimen was tested, which assay was used, what the assay was designed to recognize, and whether a chemically specific confirmation followed.

Start with the distinction between screening and confirmation

Many initial urine drug screens are immunoassays. They use antibodies to detect a target drug class or a structurally related compound. Their speed makes them useful for triage, but their response can be affected by assay design, cutoff, cross-reactivity, and the particular specimen.

A screening result is therefore ordinarily treated as presumptive. Confirmation by gas or liquid chromatography coupled with mass spectrometry addresses a different question with greater chemical specificity. Counsel should determine whether confirmation was performed, which analytes were reported, and whether the laboratory retained the raw data.

Do not rely on a generic list of medications

Published reviews describe medications and other compounds that have produced unexpected amphetamine-class screening results. Those publications are useful for identifying questions, not for proving what happened in a particular specimen. Cross-reactivity may be manufacturer-specific, reagent-specific, concentration-dependent, and different across specimen matrices.

The investigation should identify the exact test platform and obtain the applicable package insert, cross-reactivity tables, validation or verification materials, cutoff, lot information, and quality-control records. The medication history should then be compared with evidence relevant to that assay. A reported medication alone does not establish interference.

A methamphetamine result may raise a source question

Methamphetamine exists in stereoisomeric forms. Certain legitimate products and medications can produce methamphetamine or related metabolites, while illicit methamphetamine is commonly associated with a different isomeric pattern. A non-chiral confirmation that reports only “methamphetamine” may not resolve that source question.

When the factual history makes a legitimate source plausible, counsel should determine whether enantiomer-specific or chiral testing was performed. Isomer testing may help evaluate source, but it does not by itself establish impairment, dose, intent, or the exact time of use.

Urine detection is not the same as impairment

Urine is primarily an excretion matrix. A properly confirmed urine result may support prior exposure, but it generally does not measure the concentration circulating in blood at the time of an event. Hydration, urine pH, metabolism, dose pattern, collection time, and the laboratory’s reporting rules may all affect the result.

That distinction matters whenever a party uses a urine result to argue unsafe performance, intoxication, or causation. The proponent still must connect the analytical finding to the relevant time and functional question using appropriate evidence. A qualitative screen does not supply that connection by itself.

Records to request

the original screening result and every amended report;
specimen labels, seals, collection records, and chain of custody;
specimen-validity results, including creatinine, specific gravity, pH, and oxidant testing when performed;
the assay manufacturer, model, reagent lot, target class, and cutoff;
the package insert and laboratory validation or verification materials;
calibrators, controls, instrument output, review records, and corrective actions;
confirmation data, including chromatograms, spectra, transitions, calculations, and reporting criteria;
medication, over-the-counter product, supplement, and exposure history;
chiral or isomer testing when methamphetamine source is disputed; and
the laboratory’s standard operating procedures in effect on the testing date.

Questions for expert review

Was the result a screening result, a confirmed result, or both?
Did the confirmation identify the same analyte implicated by the screen?
Was the method appropriate for the specimen and reporting purpose?
Could a documented medication, metabolite, or legitimate product affect this exact assay?
Would stereoisomer testing help answer a disputed source question?
What can the urine result support about exposure, and what can it not support about timing or impairment?
Do the chain-of-custody, quality-control, and raw analytical records support the reported conclusion?

Why early review matters

Testing issues are easier to evaluate while the specimen, raw data, instrument records, and knowledgeable witnesses remain available. A preservation request and a focused demand for the complete laboratory packet can prevent the case from being reduced to a single summary line.

When the case depends on the science, your lawyer should understand the science. The Okorocha Firm evaluates matters in which drugs, alcohol, toxicology, laboratory methods, or other scientific evidence may determine the outcome. A case-specific assessment requires the actual report, laboratory packet, timeline, medication history, and governing legal standard.

Selected scientific references

Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. Journal of Analytical Toxicology. 2014;38(7):387-396. doi:10.1093/jat/bku075.
Reisfield GM, Goldberger BA, Bertholf RL. False-positive and false-negative test results in clinical urine drug testing. Bioanalysis. 2009;1(5):937-952. doi:10.4155/bio.09.81.
Smith ML, Nichols DC, Underwood P, et al. Methamphetamine and amphetamine isomer concentrations in human urine following controlled Vicks VapoInhaler administration. Journal of Analytical Toxicology. 2014;38(8):524-527. doi:10.1093/jat/bku077.